Historical Controls For Epilepsy Studies To Be Considered By Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Lamictal XR and several drugs in the pipeline could see their quest for monotherapy indications affected by what the Peripheral and Central Nervous System Drugs Advisory Committee decides.
You may also be interested in...
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.
GSK Lamictal's New Warning On Aseptic Meningitis May Help Pfizer's Lyrica
On-patent antiepileptics may have another arrow in their promotional quivers after the now-generic lamotrigine gets a label update with reports of 40 cases of aseptic meningitis.